Amnesia, Transient Global Clinical Trial
— EMOTICTUSOfficial title:
Assessment of Emotional Memory During Transient Global Amnesia
Verified date | January 2024 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
There are few studies on the role played by emotions in transient global amnesia (TGA), in particular with regard to their impact on the functioning of memory. The study investigators wish to better understand the link between episodic memory, emotional state and psychogenic factors during TGA. It would be interesting to see if the patients suffering from TGA triggered by a psychological shock process emotional information differently from those whose TGA was triggered by an "organic" shock (physical effort, trauma, etc.). Finally, amnesic stroke is a good model for better understanding the function of the hippocampus, in particular of the CA1 region, in episodic memory.
Status | Terminated |
Enrollment | 2 |
Est. completion date | June 12, 2023 |
Est. primary completion date | June 12, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject with no history of transient global amnesia or neurological or psychiatric pathology. - Patients with a transient global amnesia according to the criteria of Hodges and Warlow (1990) in the acute phase (i.e. within 24 hours after the onset of the stroke), accompanied by a trusted person - The patient must have given their free and informed consent and signed the consent form - The patient must be a member or beneficiary of a health insurance plan Exclusion Criteria: - The subject is participating in another study, or is in a period of exclusion determined by a previous study - The subject refuses to sign the consent - It is impossible to give the subject informed information - The patient is under safeguard of justice or state guardianship - The patient is pregnant or breastfeeding - Presence of a focal neurological pathology that may explain the symptoms, history of epilepsy or psychiatric disorders. - Hypersensitivity to iodinated contrast media. - Known allergy to 18-FDG. Non-inclusion criteria concerning control subjects: - Presence of disorders on neurological assessment - Presence of cognitive disorders on the neuropsychological assessment (z-score <-1.65 on the RBANS or on the Stroop test). Exclusion criteria for the target population: • Patients will be excluded after the 1st neuropsychological assessment if episodic memory tests show complete recovery from anterograde amnesia. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nimes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Storage and retrieval capacities of information with a strong emotional valence in patients compared to healthy controls | International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral). | Day 0 | |
Primary | Ability to judge the degree of activation and emotional value associated with images | Self Assessment Manikin (SAM) | Day 0 | |
Secondary | Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline | International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral). | Day 3 | |
Secondary | Change in storage and retrieval capacities of information with a strong emotional valence in patients from baseline | International Affective Picture System (IAPS): number of correctly memorized images of each type of emotional content (15 positive, 15 negative and 15 neutral). | Month 3 | |
Secondary | Classification of event triggering transient global amnesia | Psychological/physiological | Day 0 | |
Secondary | Anxiety | Hamilton Scale: where score = 7 is absence of depression; 8-15 is minor depression and 16 or more is severe depression | Day 0 | |
Secondary | Depression | Beck Depression Scale | Day 0 | |
Secondary | Mood | Befindlichkeits Skala Mood Scale | Day 0 | |
Secondary | C-score of the Groupe de REflexion pour l'Evaluation des Fonctions Exécutives (GREFEX) version of Stroop Test between patients and healthy control | Stroop Test | Day 0 | |
Secondary | Repeatable Battery for the Assessment of Neuropsychological Status between patients and healthy control | Repeatable Battery for the Assessment of Neuropsychological Status: 10 subtests combined into 5 index scores and 1 total score. | Day 0 | |
Secondary | Identification of hypometablic zones by PET compared to age- and sex-matched controls | Visual analysis of hippocampus and other topographies (Z-score); Statistical Parametric Mapping 12 | Day 0 |